Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAGMATYK long-term safety study of deucravacitinib versus ustekinumab in plaque psoriasis
2023-503766-24-00Phase 4Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 24
01
Overview
Phase 4, randomised, open-label trial in plaque psoriasis comparing Deucravacitinib with Ustekinumab (2 arms). Primary endpoint: Composite cardiovascular endpoint. Planned start May 2026; status: authorised.
02
Drugs
deucravacitinibustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-503766-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503766-24-00.